|
|
|
|
|||||
|
|
|
By Karen Roman
VERAXA Biotech AG (Nasdaq: VRXA) said it expects BiTAC molecules to be the company’s main value drivers and to dominate its pipeline development in the upcoming years, hence receiving VERAXA’s main share of investments to have a first BiTAC-T cell engager candidate ready by early 2028.
The company stated its half-year progress is aligned to its pipeline and partnering strategy, while it will also finance its growth by early monetizing selected non-BiTAC assets.
“Interest in novel technologies and drug development programs in the T cell engager and ADC space continues to be at a record high in the pharmaceutical industry,“ said Heinz Schwer, Ph.D., MBA, VERAXA’s Chief Business Officer. “The recent BIO International Partnering Conference turned out to be a well-timed opportunity for us to meet with potential new partners and also to intensify our ongoing discussions.”
Contact:
Click HERE to follow us on LinkedIn
The post The Cancer Therapy Strategy VERAXA Is Betting the Company On appeared first on ExecEdge.
| Jul-13 | |
| Jul-13 | |
| Jul-10 | |
| Jul-09 | |
| Jul-06 | |
| Jul-06 | |
| Jul-06 | |
| Jul-02 | |
| Jul-02 | |
| Jul-02 | |
| Jul-01 | |
| Jun-25 | |
| Jun-24 | |
| Jun-24 | |
| Jun-24 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite